Pfizer Inc(PFE-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low28.52
Day High28.95
Open:28.79
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
Biossil Inc. Co-founders Anthony Mouchantaf at left, and Alexander Mosa, are photographed at their office in Toronto, Monday, March 30, 2026. (Cole Burston/The Globe and Mail)
the globe and mail

Biossil raises $153-million in OpenAI-led funding to bring resuscitated drugs to market

Toronto startup uses AI to save once-promising drug candidates from pharmaceutical discard pile
Motley Fool
With the Market Flashing Warning Signs Not Seen Since the Dot-Com Bust, Is Pfizer's 6% Yield a Safe Haven or a Trap?
Motley Fool
Here Are My Top 2 High-Yield Healthcare Stocks to Buy Now
Zacks Investment Research
Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?
Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?
Motley Fool
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
Motley Fool
5 Dividend Stocks Yielding Over 5% With Fortress Financial Profiles to Buy Now
Motley Fool
Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks.
Tipranks
Pfizer’s RSV Revaccination Trial Targets Durable Booster Revenue in High‑Risk Adults
Tipranks
Pfizer Targets Cancer-Related Weight Loss With New Ponsegromab Study
Motley Fool
D-Wave Quantum vs. QuantumScape: Which Moonshot Tech Stock Is a Better Buy in 2026?
Motley Fool
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
Tipranks
Pfizer’s Japanese RSV Vaccine Study Wraps Up, Expanding Adult Market Potential
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Scholar Rock Holding (SRRK) and Immunovant (IMVT)
Tipranks
RBC Capital Remains a Hold on Pfizer (PFE)
Zacks Investment Research
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
Zacks Investment Research
Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio?
Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio?
MarketBeat
Treasury Yields Hit a 19-Year High—These 2 Bond ETFs Offer Monthly Income
MarketBeat.com
Motley Fool
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Tipranks
Analysts Conflicted on These Healthcare Names: Pfizer (PFE), Celldex (CLDX) and Vertex Pharmaceuticals (VRTX)
MarketBeat
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
MarketBeat.com

Profile

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.'The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Market data provided by Barchart. Exchange delay details and data provider terms here. Information may be delayed, is provided 'as is' and is solely for informational purposes, and not for trading, investment or advice.